Market Overview

Uveal melanoma| A Pipeline Analysis Report 2018| Technavio

Share:

Technavio has announced their latest pipeline analysis report on the uveal
melanoma market
. The report includes a detailed analysis of the
pipeline molecules under investigation within the defined data
collection period to treat uveal melanoma.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180721005010/en/

Technavio has published a new report on the drug development pipeline for uveal melanoma, including  ...

Technavio has published a new report on the drug development pipeline for uveal melanoma, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report by Technavio
presents a detailed analysis of the market, including regulatory
framework, drug development strategies, recruitment strategies, and key
companies that are expected to play an essential role in the growth of
the market in the future.

This report is available at a USD 1,000 discount for a limited time
only:
View
market snapshot before purchasing

Uveal melanoma: Market overview

Uveal melanoma is one of the most common ocular melanomas. It arises
from melanocytes in the iris, ciliary body, or choroid. Early diagnosis
and local treatment are crucial as the survival rate depends on them.
However, approximately 50% of patients will develop metastatic disease
with 6-12 months survival from metastatic diagnosis. The genomic
analysis led to the development of gene-expression profiles, which
predict metastatic progression effectively, however no adjuvant therapy
has been shown to prolong the survival till date. New insights into the
molecular biology of uveal melanoma have found frequent activating
mutations in genes encoding for the G-protein subunit, GNAQ, and GNA11.

According to a senior market research analyst at Technavio, "Uveal
melanoma is one of the most common ocular malignancies in adults. This
malignancy in the ocular tract is mostly diagnosed at late adulthood,
that is, 65 years and above and the incidence rate usually has a
progressive nature with peak near 70 years. The incidence of uveal
melanoma varies by gender, race, and country."

Uveal melanoma: Segmentation analysis

This pipeline analysis report segments the uveal melanoma market based
on therapies employed (monotherapy, combination therapy and
monotherapy/combination therapy), RoA (oral, intravenous, intravitreal,
and intraarterial), therapeutic modality (small molecule, cell therapy,
fusion protein, peptide, recombinant enzyme, monoclonal antibody, and
virus), targets (arginase, CXCR4 receptor, MEK1 and MEK2, and others),
MoA (arginase replacement, CXCR4 receptor antagonist, MEK1 and MEK2
inhibitor, and others), geographical segmentation (US, Europe, UK,
Australia, Canada, and Taiwan) and recruitment status (recruiting,
completed, active, not recruiting and not yet recuiting). It provides an
in-depth analysis of the prominent factors influencing the market,
including drivers, opportunities, trends, and industry-specific
challenges.

More than 57% of the molecules that are being investigated for the
treatment of uveal melanoma are small molecule.

Looking for more information on this market? Request
a free sample report

Technavio's sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio's comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at media@technavio.com.

View Comments and Join the Discussion!